Ask AI

Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma

Podcast
This activity is available for 0.50 CME/CE credit(s).

Released: September 30, 2026

Expiration: March 29, 2027

See Activity Collection

In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of alternative targets. Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates, bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.

Sequencing for RR MM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your podcast.
1.

How many people with multiple myeloma do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

You are planning therapy sequencing for a patient with multiple myeloma experiencing disease relapse. In considering use of BCMA-targeted therapies, which of the following BCMA-directed treatment modalities is suggested to be associated with an increased risk of BCMA binding-site mutations and BCMA loss when patients relapse during treatment?

4.

Based on current evidence in R/R multiple myeloma, which novel therapeutic approach is supported by data demonstrating improved outcomes?